Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024
Financial Highlights Direct MagnetOsTM sales rose by 149% to CHF 50.6 million in the first nine months of 2024, fro…
Kuros Biosciences AG
Kuros Biosciences Reports First Half of 2024 Results
Financial Highlights Direct MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; th…
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Annual General Meeting of Kuros Biosciences approves all resolutions
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today…
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for inter…
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in…
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…
